This is the authors' abstract. We don't add key points for this paper.
After the first report of the mobile colistin resistance gene mcr-1 in 2015, 10 mcr variants were identified among antibiotic-resistant Enterobacterales and were mostly located on plasmids.1,2 The mcr genes encode phosphoethanolamine transferases capable of modifying Lipid A in membrane-associated LPS, thereby ultimately leading to colistin resistance.3 Colistin is considered a last-resort antibiotic for treatment of human Enterobacterales infections, but was also being used in veterinary medicine in the Netherlands in 2021.4 Until now, the presence of mcr-4 has not been described before in The Netherlands. The major objective of this study was to analyse mcr-4-encoding plasmids from Enterobacterales obtained from humans and livestock in the Netherlands. To address this, a search for mcr-4-containing Enterobacterales isolates was performed in two surveillance databases containing Illumina short-read next-generation sequencing (NGS) data. These include the carbapenemase-producing Enterobacterales (CPE) surveillance collection from the National Institute for Public Health and the Environment (RIVM) and the livestock resistance monitoring collection from Wageningen Bioveterinary Research (WBVR). In addition, two clinical isolates of the Zuyderland Medical Center (ZMC) were analysed by the Maastricht University Medical Centre (MUMC). The national CPE surveillance collection of the RIVM was searched for unique CPE and non-CPE isolates in the period from 2012 until 2020, in which only the first bacterial species and carbapenemase allele combination per person were included, yielding 3008 Enterobacterales isolates. This revealed two Enterobacter spp. (0.07%) with MLST ST54 that carried mcr-4.3. Average nucleotide identity (ANI) calculation using http://enve-omics.ce.gatech.edu/ani/index of the Enterobacter sp. ST54 with Enterobacter kobei strain UCI 23 (GenBank accession NZ_KI973153.1) revealed an ANI of 99.09%, demonstrating that the mcr-4.3-carrying isolates were E. kobei. The collection of the WBVR in the period from 2018 until 2021 revealed that 4 out of 1200 veal calf isolates (0.3%) harboured mcr-4.6. Three mcr-4.6-containing plasmids, one from Hafnia paralvei and two from Escherichia coli were included in this study. The collection of the ZMC contained two E. kobei ST54 isolates with mcr-4.3 isolated from hospitalized patients. Isolates were also subjected to Nanopore long-read sequencing by different in-house methods.5,6 Hybrid assembly of short-read and long-read sequencing data was performed using Unicycler (v.0.4.8, default settings) to reconstruct mcr-4 plasmids, which were compared to internationally reported mcr-4 plasmid sequences from NCBI (accessed 14 October 2022) using BioNumerics (v7.6.3).7 Hybrid mcr-4 plasmid assemblies are available in GenBank (BioProject accession number PRJNA941496). Colistin resistance was confirmed using a standardised broth microdilution (BMD; Micronaut MIC strip colistin, Merlin), as previously described.8 Seven isolates carried mcr-4-like alleles and had varying resistomes (Figure 1a). In addition to mcr-4.3, the RIVM_C009363 isolate contained the ant(2′′)-Ia, blaACT-9-like, blaCTX-M-9, fosA, mcr-9.1, qnrA1, sul1 and tet(A) resistance genes and lacked a carbapenemase gene. The RIVM_C014549 isolate was multi-resistant, containing the aac(6′)-Ib-cr, aac(6′)-Ib3, aadA1, aph(3′′)-Ib, aph(3′)-XV, aph(6)-Id, blaACT-9, blaSHV-12, blaVIM-1, catB2, dfrA14, fosA, mcr-9.1, mph(A), qnrS1 and sul1/2 genes. The E. kobei isolates MUMC-1 and MUMC-2 also belonged to MLST ST54, but were not clonally related to the RIVM_C014549 and RIVM_C009363 E. kobei isolates since they differed by 191 to 270 SNPs as inferred using split K-mer analysis using default settings. These isolates contained the mcr-4.3, aph(6)-Id*, aph(3′′)-Ib*, sul2*, catA1*, blaCTX-M-15*, dfrA14, oqxA10, oqxB4, blaOXA-1, aac(6′)-Ib-cr, aac(3)-IIe, aadA1*, mcr-9.1, qnrB1, blaACT-64, tet(A) (*absent in MUMC-1) resistance genes. The livestock E. coli isolates (WUR-NRS20181383 and WUR-NRS20181408) were from ST216, and contained the aadA1, blaTEM-1, blaEC-15, dfrA1, sul1 and tet(B) resistance genes. The H. paralvei isolate (WUR-NRS20180341) contained the aadA1, blaACC-1b, mph(B), sul1, dfrA1, mcr-9.1 and tet(B) genes. None of the seven isolates carrying mcr-4 contained mutations in the pmrAB genes, known to be associated with colistin resistance, as inferred using PointFinder v4.1.9 In silico characterization of mcr-4-containing plasmids. (a) Short-read sequencing-based molecular characteristics of the mcr-4-carrying isolates analysed in this study. (b) Comparison of mcr-4 plasmids from the Netherlands in context with NCBI-retrieved plasmids. The % G + C content and plasmid size in bp is indicated. The presence of mcr-4 alleles and replicons is indicated by squares. Heatmap indicating percentage identity. (c) Alignment of all mcr-4-harbouring plasmids from the Netherlands with one E. kobei plasmid (pIB2020_ColE_MCR, CP059482.1) from Italy using CLC Genomics Workbench (v22.0.2). Plasmids were rotated and the mcr-4 allele was set as starting point for comparison. Seven highly similar (76%–99%) and small (12.8–14.1 kb) mcr-4 plasmids with a ColE10 replicon were identified with either an mcr-4.3 allele in four human E. kobei isolates (MIC colistin ≤1 mg/L), or an mcr-4.6 allele in three livestock-associated isolates (MIC colistin 4–8 mg/L) collected between 2012 and 2021 (Figure 1b). More specifically, the MUMC-1_plasmid_5, MUMC-2_plasmid_4 and pRIVM_C009363_4 were 99% identical plasmids of 12.8 kb with a %G + C of 46.92%. The WUR-NRS20180341_plasmid_3, WUR-NRS20181383_mcr4 and WUR-NRS-20181408_mcr4 had slightly different %G + C and an mcr-4.6 allele possibly conferring resistance to colistin. Four human E. kobei isolates (MUMC-01, MUMC-02, RIVM_C014549, RIVM_C009363) carried both mcr-4.3 and mcr-9; mcr-9 is not associated with colistin resistance in Enterobacter.10,11 Dutch livestock-retrieved isolates with mcr-4.6 plasmids differed from the human-derived plasmids by one SNP in the mcr-4.3 gene, leading to an mcr-4.6 allelic variant, all exhibiting resistance to colistin.12,13 The mcr-4 plasmids identified among Enterobacterales in the Netherlands were distinct from the mcr-4 plasmids in the NCBI database (Figure 1b). However, one E. kobei plasmid (pIB2020_ColE_MCR, CP059482.1) from Italy from 2019 closely resembled the mcr-4.3 and mcr-4.6 plasmids from the Netherlands, suggesting international spread.14 The Dutch mcr-4 plasmid architecture was comparable and comprised the phosphoethanolamine lipid A transferase gene mcr-4, followed by a type II toxin/antitoxin system, TraD conjugal transfer protein, MobA/X mobilization proteins and transposases (Figure 1c). The pRIVM_C014549_3 was different from the other mcr-4 plasmids obtained in the Netherlands. To test mcr-4-mediated colistin resistance, two strategies were employed. Firstly, cloning of mcr-4.3 and mcr-4.6 with and without native promotor using primers MCR4_ownpromotorF: CACGGGCAAAGATCGGAGGG, MCR4_reverse: TCAGATCTCGTTGTAATTTTCAAGG and MCR4_withoutownpromotorF: GAGGTCAAGCTTGTATTGTTTTT into pGEM®-T Easy (Invitrogen) in E. coli DH10β was performed according to the manufacturer’s instructions. Plating was done on LB agar plates with 0, 0.125, 0.25, 0.5, 1 or 2 mg/L colistin and with ampicillin (50 mg/L). To avoid overexpression of the mcr-4 genes, IPTG was omitted in the LB agar plates (no blue–white screening). No colonies were found after overnight incubation at 37°C on plates containing colistin. Also, induction with IPTG for the native and non-native mcr-4 promotor constructs, did not result in colistin resistant colonies. Seven of the eight selected colonies that grew on LB agar plates with only ampicillin showed inverted mcr-4 inserts, as determined by sequencing. Secondly, transformation of an Acinetobacter baumannii (BioSample: ERS7182715, MIC colistin 0.5 mg/L) with mcr-4.3 and mcr-4.6 plasmid DNA isolated from isolate MUMC-1 and WUR_NRS20181383, respectively, was performed. After transformation of A. baumannii with either mcr-4.3 or mcr-4.6 plasmids, only colonies were observed on plates with colistin concentration up to and including 0.25 mg/L, indicating there was no change in colistin resistance for this strain. In summary, the occurrence of mcr-4 plasmids among Enterobacterales is low in the Netherlands. The mcr-4.3 allele in E. kobei and the mcr-4.6 allele in livestock E. coli and H. paralvei likely do not encode for colistin resistance in the human and livestock isolates. A recent study also failed to detect colistin resistance in E. kobei ST54 co-harbouring mcr-4.3 and mcr-9 and is in line with this study.15 In contrast, mcr-4.3 conferred colistin resistance in A. baumannii and Acinetobacter nosocomialis,16,17 suggesting species-specific functionality of this colistin resistance gene, but could not be confirmed in the A. baumannii isolate analysed in this study. The mcr-4 plasmids from human and livestock were virtually identical, suggesting unnoticed horizontal dissemination of these plasmids in the Netherlands. We thank all the members of the Dutch CPE surveillance study group and the Dutch medical microbiology laboratories for submitting Enterobacterales isolates to the RIVM for the national CPE surveillance programme. A. Maijer-Reuwer, ADRZ medisch centrum, Department of Medical Microbiology, Goes; M. A. Leversteijn-van Hall, Alrijne Hospital, Department of Medical Microbiology, Leiden; W. van den Bijllaardt, Amphia Hospital, Microvida Laboratory for Microbiology, Breda; R. van Mansfeld, Amsterdam UMC—location AMC, Department of Medical Microbiology and Infection Control, Amsterdam; K. van Dijk, Amsterdam UMC—location VUmc, Department of Medical Microbiology and Infection Control, Amsterdam; B. Zwart, Atalmedial, Department of Medical Microbiology, Amsterdam; B. M. W. Diederen, Bravis Hospital/ZorgSaam Hospital Zeeuws-Vlaanderen, Department of Medical Microbiology, Roosendaal/Terneuzen; J. W. Dorigo-Zetsma, TergooiMC, Central Bacteriology and Serology Laboratory, Hilversum; D. W. Notermans, Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven; A. Ott, Certe, Medical Microbiology Groningen, Drenthe, Groningen; W. Ang, Comicro, Department of Medical Microbiology, Hoorn; J. da Silva, Deventer Hospital, Department of Medical Microbiology, Deventer; A. L. M. Vlek, Diakonessenhuis Utrecht, Department of Medical Microbiology and Immunology, Utrecht; A. G. M. Buiting, Elisabeth-TweeSteden (ETZ) Hospital, Department of Medical Microbiology and Immunology, Tilburg; L. G. M. Bode, Erasmus University Medical Center, Department of Medical Microbiology and Infectious Diseases, Rotterdam; S. Paltansing, Franciscus Gasthuis & Vlietland, Department of Medical Microbiology and Infection Control, Rotterdam; A. J. van Griethuysen, Gelderse Vallei Hospital, Department of Medical Microbiology, Ede; M. den Reijer, Star-shl diagnostic centre, Department of Medical Microbiology, Rotterdam; M. J. C. A. van Trijp, Groene Hart Hospital, Department of Medical Microbiology and Infection Prevention, Gouda; M. Wong, Haga Hospital, Department of Medical Microbiology, ‘s-Gravenhage; A. E. Muller, HMC Westeinde Hospital, Department of Medical Microbiology, ‘s-Gravenhage; M. P. M. van der Linden, IJsselland hospital, Department of Medical Microbiology, Capelle a/d Ijssel; M. van Rijn, Ikazia Hospital, Department of Medical Microbiology, Rotterdam; S. B. Debast, Isala Hospital, Laboratory of Medical Microbiology and Infectious Diseases, Zwolle; K. Waar, Certe, Medical Microbiology Friesland, Noordoostpolder, Leeuwarden; E. Kolwijck, Jeroen Bosch Hospital, Department of Medical Microbiology and Infection Control, ‘s-Hertogenbosch; N. Al Naiemi, LabMicTA, Regional Laboratory of Microbiology Twente Achterhoek, Hengelo; T. Schulin, Laurentius Hospital, Department of Medical Microbiology, Roermond; S. Dinant, Maasstad Hospital, Department of Medical Microbiology, Rotterdam; S. P. van Mens, Maastricht University Medical Centre, Department of Medical Microbiology, Infectious Diseases & Infection Prevention, Maastricht; D. C. Melles, Meander Medical Center, Department of Medical Microbiology, Amersfoort; M. P. A. van Meer, Rijnstate Hospital, Laboratory for Medical Microbiology and Immunology, Velp; J. W. T. Cohen Stuart, Noordwest Ziekenhuisgroep, Department of Medical Microbiology, Alkmaar; P. Gruteke, OLVG Lab BV, Department of Medical Microbiology, Amsterdam; I. T. M. A. Overdevest, PAMM, Department of Medical Microbiology, Veldhoven; A. van Dam, Public Health Service, Public Health Laboratory, Amsterdam; I. Maat, Radboud University Medical Center, Department of Medical Microbiology, Nijmegen; B. Maraha, Albert Schweitzer Hospital, Department of Medical Microbiology, Dordrecht; J. C. Sinnige, Regional Laboratory of Public Health, Department of Medical Microbiology, Haarlem; E. E. Mattsson, Reinier de Graaf Groep, Department of Medical Microbiology, Delft; N. van Maarseveen, Saltro Diagnostic Centre, Department of Medical Microbiology, Utrecht; E. de Jong, Slingeland Hospital, Department of Medical Microbiology, Doetinchem; S. J. Vainio, St Antonius Hospital, Department of Medical Microbiology and Immunology, Nieuwegein; E. Heikens, St Jansdal Hospital, Department of Medical Microbiology, Harderwijk; R. Steingrover, St. Maarten Laboratory Services, Department of Medical Microbiology, Cay Hill (St. Maarten); A. Troelstra, University Medical Center Utrecht, Department of Medical Microbiology, Utrecht; E. Bathoorn, University of Groningen, Department of Medical Microbiology, Groningen; J. de Vries, VieCuri Medical Center, Department of Medical Microbiology, Venlo; D. W. van Dam, Zuyderland Medical Centre, Department of Medical Microbiology and Infection Control, Sittard-Geleen; E. I. G. B. de Brauwer, Zuyderland Medical Centre, Department of Medical Microbiology and Infection Control, Heerlen; T. Halaby, Analytical Diagnostic Center N.V. Curaçao, Department of Medical Microbiology, Willemstad (Curaçao); H. Berkhout, Canisius Wilhelmina Hospital, Department of Medical Microbiology and Infectious Diseases, Nijmegen. This study was carried out as part of the Dutch National CPE surveillance, as part of the regular activities of the RIVM, financed by the Dutch Ministry of Health, Welfare and Sport. Part of the work was performed in the WBVR and was funded by the Dutch Ministry for Agriculture, Nature and Food Quality through the project ‘Antimicrobial resistance monitoring in animals’ grant number WOT-01-002-038. The authors have nothing to disclose. Ethical approval was not needed for the study, since it was based on surveillance data only. Samples from which the isolates were cultured were all taken as part of routine healthcare.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Jamin et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: